This large single-centre analysis evaluated whether earlier liver transplantation improves survival in patients with perihilar cholangiocarcinoma (pCCA) treated with standardised neoadjuvant therapy and transplant protocol. The key question: Does transplanting within 6 months of protocol registration improve outcomes?
This large single-centre analysis evaluated whether earlier liver transplantation improves survival in patients with perihilar cholangiocarcinoma (pCCA) treated with standardised neoadjuvant therapy and transplant protocol.
The key question:
Does transplanting within 6 months of protocol registration improve outcomes?
Study Overview
392 patients in the intention-to-treat cohort
256 underwent liver transplantation
Median time to transplant/dropout: ~5.7 months
Key Findings
Shorter wait times (0–3 months) did NOT improve overall survival.
Waiting longer (≥6 months) did not worsen intention-to-treat survival.
Importantly, among transplanted patients:
Waiting ≥6 months was associated with lower post-transplant mortality.
Survival benefit became more pronounced beyond 9 months.
Waiting time was not associated with increased residual tumour in the explant.
Clinical Interpretation
This study challenges the assumption that “earlier is better” for transplant in pCCA.
A minimum 6-month waiting period may:
Allow biological selection of favourable tumour behaviour
Reduce post-transplant mortality
Maintain overall survival in the broader cohort
Take-Home Message for Hepatobiliary & Transplant Teams
Transplantation within 6 months of registration does not enhance survival, and waiting ≥6 months may optimise outcomes without compromising overall patient survival.
This reinforces the importance of disciplined protocol adherence and biological selection in pCCA transplant programs.
Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...
Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...
Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...
Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...
Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...
Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.